Insulet Corp
NASDAQ:PODD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
161.02
275.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Insulet Corp
Insulet Corp
Total Receivables
Insulet Corp
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Insulet Corp
NASDAQ:PODD
|
Total Receivables
$375.6m
|
CAGR 3-Years
49%
|
CAGR 5-Years
37%
|
CAGR 10-Years
23%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Receivables
$3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$3.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$7.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
What is Insulet Corp's Total Receivables?
Total Receivables
375.6m
USD
Based on the financial report for Sep 30, 2024, Insulet Corp's Total Receivables amounts to 375.6m USD.
What is Insulet Corp's Total Receivables growth rate?
Total Receivables CAGR 10Y
23%
Over the last year, the Total Receivables growth was 39%. The average annual Total Receivables growth rates for Insulet Corp have been 49% over the past three years , 37% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet
